Objective:To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly patients with coronary heart disease(CHD)and heart failure.Methods:Plasma omentin-1 and visfatin levels were measured in 90...Objective:To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly patients with coronary heart disease(CHD)and heart failure.Methods:Plasma omentin-1 and visfatin levels were measured in 90 subjects(29 stable angina pectoris(SAP)cases,30 unstable angina pectoris(UAP)cases and 31 age-and sex-matched healthy controls(age≥60 years)by enzyme-linked immunosorbent assay methods.According to the New York Heart Association classification.59 CHDs were divided into three groups:functional I class,11 cases;functional II/III class,36 cases;and functional IV class,12 cases.Results:The plasma level of omentin-1in CHO patients was significantly lower than thai of the control group.Otnenlin-lin SAP group and UAP group were significantly lower compared to the control group(there was no statistical significance between UAP group and SAP group;P>0.05).The plasma level of visfatin in CHD patients was significandy higher than that of the control group.Similarly,visfatin in SAP group and UAP group were all significantly higher compared to the control group,while there was no statistical significance between UAP group,and SAP group.The plasma omentin-1 level was negatively correlated with SBP(r=-0.264,P<0.05),positively correlated with HDL-c level(r=0.271,P<0.05);the plasma visfatin level was positively correlated with TC(r=0.292,P<0.05),negatively correlated with HDL-c level(r=-0.266,P<0.05).There was a negative correlation between plasma omentin-1 and visfatin levels(r=-0.280,P<0.05).Moreover,multiple linear stepwise regression analysis showed that omentin-1 and visfatin levels might be affected by HDL-c level.Logistic regression analysis showed that visfatin could be an independent risk factor of CHD.Conclusions:Decreased levels of omentin-1 and increased levels of visfatin may be involved in the occurrence and development of CHD.Omentin-1 and visfatin,independently,may be protective and pro-inflammatory cytokines.Additionally,both omentin-1 and visfatin may be related to lipid metabolism.Visfatin may b展开更多
目的观察活心丸(浓缩丸)治疗冠心病稳定性心绞痛的有效性及安全性。方法采用多中心、随机、双盲、安慰剂对照的临床研究,对131例冠心病稳定性心绞痛(气虚血瘀证)患者随机分组,分别采用活心丸(浓缩丸)或安慰剂进行治疗8周,其中48例进行...目的观察活心丸(浓缩丸)治疗冠心病稳定性心绞痛的有效性及安全性。方法采用多中心、随机、双盲、安慰剂对照的临床研究,对131例冠心病稳定性心绞痛(气虚血瘀证)患者随机分组,分别采用活心丸(浓缩丸)或安慰剂进行治疗8周,其中48例进行心电图平板运动试验,观察治疗前后心绞痛症状、硝酸甘油停减率、心电图平板运动试验(总运动时间、运动诱发ST段下降0.1 m V或出现心绞痛的时间、诱发心电图ST段最大下移程度、运动诱发心电图ST段下移超过0.1 m V的导联数、运动代谢当量)、西雅图心绞痛调查量表总评分、中医证候变化情况、炎性因子以及血脂。结果治疗后,试验组心绞痛症状总积分明显低于对照组(P<0.01),试验组硝酸甘油停减率明显高于对照组(P<0.01),试验组西雅图心绞痛量表总分明显高于对照组(P<0.01),试验组中医证候疗效明显高于对照组(P<0.01)。心电图平板运动试验,试验组的ST段下降≥0.1 m V导联数较治疗前的减少数量明显高于对照组(P<0.01)。试验组V4、V5、V6导联ST段最大下移幅度较对照组明显降低(P<0.05)。炎性因子与血脂指标组间均没有明显统计学差异(P>0.05)。试验组不良事件发生率与对照组相当。结论活心丸(浓缩丸)治疗冠心病稳定性心绞痛的效果显著优于对照组,且具有良好的安全性和耐受性。展开更多
基金funded by the Natural Science Foundation of Hunan Province(No.12JJ5044)
文摘Objective:To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly patients with coronary heart disease(CHD)and heart failure.Methods:Plasma omentin-1 and visfatin levels were measured in 90 subjects(29 stable angina pectoris(SAP)cases,30 unstable angina pectoris(UAP)cases and 31 age-and sex-matched healthy controls(age≥60 years)by enzyme-linked immunosorbent assay methods.According to the New York Heart Association classification.59 CHDs were divided into three groups:functional I class,11 cases;functional II/III class,36 cases;and functional IV class,12 cases.Results:The plasma level of omentin-1in CHO patients was significantly lower than thai of the control group.Otnenlin-lin SAP group and UAP group were significantly lower compared to the control group(there was no statistical significance between UAP group and SAP group;P>0.05).The plasma level of visfatin in CHD patients was significandy higher than that of the control group.Similarly,visfatin in SAP group and UAP group were all significantly higher compared to the control group,while there was no statistical significance between UAP group,and SAP group.The plasma omentin-1 level was negatively correlated with SBP(r=-0.264,P<0.05),positively correlated with HDL-c level(r=0.271,P<0.05);the plasma visfatin level was positively correlated with TC(r=0.292,P<0.05),negatively correlated with HDL-c level(r=-0.266,P<0.05).There was a negative correlation between plasma omentin-1 and visfatin levels(r=-0.280,P<0.05).Moreover,multiple linear stepwise regression analysis showed that omentin-1 and visfatin levels might be affected by HDL-c level.Logistic regression analysis showed that visfatin could be an independent risk factor of CHD.Conclusions:Decreased levels of omentin-1 and increased levels of visfatin may be involved in the occurrence and development of CHD.Omentin-1 and visfatin,independently,may be protective and pro-inflammatory cytokines.Additionally,both omentin-1 and visfatin may be related to lipid metabolism.Visfatin may b
文摘目的观察活心丸(浓缩丸)治疗冠心病稳定性心绞痛的有效性及安全性。方法采用多中心、随机、双盲、安慰剂对照的临床研究,对131例冠心病稳定性心绞痛(气虚血瘀证)患者随机分组,分别采用活心丸(浓缩丸)或安慰剂进行治疗8周,其中48例进行心电图平板运动试验,观察治疗前后心绞痛症状、硝酸甘油停减率、心电图平板运动试验(总运动时间、运动诱发ST段下降0.1 m V或出现心绞痛的时间、诱发心电图ST段最大下移程度、运动诱发心电图ST段下移超过0.1 m V的导联数、运动代谢当量)、西雅图心绞痛调查量表总评分、中医证候变化情况、炎性因子以及血脂。结果治疗后,试验组心绞痛症状总积分明显低于对照组(P<0.01),试验组硝酸甘油停减率明显高于对照组(P<0.01),试验组西雅图心绞痛量表总分明显高于对照组(P<0.01),试验组中医证候疗效明显高于对照组(P<0.01)。心电图平板运动试验,试验组的ST段下降≥0.1 m V导联数较治疗前的减少数量明显高于对照组(P<0.01)。试验组V4、V5、V6导联ST段最大下移幅度较对照组明显降低(P<0.05)。炎性因子与血脂指标组间均没有明显统计学差异(P>0.05)。试验组不良事件发生率与对照组相当。结论活心丸(浓缩丸)治疗冠心病稳定性心绞痛的效果显著优于对照组,且具有良好的安全性和耐受性。
